Then, we developed a morphometric signature that can reflect HER2‐positive tumours with active oncogenic activity and validated it using HER2‐E PAM50 molecular sub‐type and evaluated the prognostic and predictive validity of the developed signature. The gene discussed is ERBB2; the disease is neoplasm.